suramin has been researched along with Motor Neuron Disease in 2 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Motor Neuron Disease: Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL." | 2.68 | Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ( Bitton, RJ; Bowden, C; Cooper, MR; Dalakas, MC; Figg, WD; Headlee, D; Myers, CE; Reed, E; Venzon, DJ, 1995) |
| " We conclude that: (1) serial electrophysiologic monitoring is helpful for early detection of suramin-induced neuropathy; and (2) fixed dosing schedule of suramin without adaptive control does not lead to an increased incidence of demyelinating neuropathy when compared to adaptively controlled dosing schedules." | 2.68 | Evaluation of neuropathy in patients on suramin treatment. ( Arora, R; Dhand, UK; Janisch, L; Kobayashi, K; Martin, B; Petersen, MV; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitton, RJ | 1 |
| Figg, WD | 1 |
| Venzon, DJ | 1 |
| Dalakas, MC | 1 |
| Bowden, C | 1 |
| Headlee, D | 1 |
| Reed, E | 1 |
| Myers, CE | 1 |
| Cooper, MR | 1 |
| Soliven, B | 1 |
| Dhand, UK | 1 |
| Kobayashi, K | 1 |
| Arora, R | 1 |
| Martin, B | 1 |
| Petersen, MV | 1 |
| Janisch, L | 1 |
| Vogelzang, NJ | 1 |
| Vokes, EE | 1 |
| Ratain, MJ | 1 |
2 trials available for suramin and Motor Neuron Disease
| Article | Year |
|---|---|
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Topics: Adult; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Melanoma; Middle Aged; Motor Neuron D | 1995 |
Evaluation of neuropathy in patients on suramin treatment.
Topics: Adult; Aged; Aged, 80 and over; Demyelinating Diseases; Female; Humans; Male; Middle Aged; Motor Neu | 1997 |